Sodium iodide
- Generic Name
- Sodium iodide
- Brand Names
- Sclerodine
- Drug Type
- Small Molecule
- Chemical Formula
- INa
- CAS Number
- 7681-82-5
- Unique Ingredient Identifier
- F5WR8N145C
- Background
Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition but is more commonly used in veterinary medicine. Radiolabelled compound, Iodide I-131, is used as a diagnostic tool to evaluate thyroid function and morphology.
- Indication
Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) .
- Associated Conditions
- Abscesses, Bleeding of the Vitreal Body, Clouding of the Lenses, Vitreous opacities, Wound
- Associated Therapies
- Total parenteral nutrition therapy
Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved
• The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.
• Key companies like Boehringer Ingelheim and Idorsia Pharmaceuticals are advancing novel therapies to improve outcomes post-myocardial infarction.
• Several promising therapies, including Selatogrel and FDY-5301, are in Phase III trials, showing potential for significant advancements.
• Recent clinical trial activities, such as the commencement of the PERFECT study and completion of enrollment in the Iocyte AMI-3 trial, highlight ongoing research efforts.
Myocardial Infarction: Promising Therapies Advance Through Clinical Trials
• Several companies are actively developing innovative therapies for myocardial infarction, with Idorsia Pharmaceuticals leading the way with its Phase III drug, selatogrel.
• Faraday Pharmaceuticals' FDY-5301, an elemental reducing agent, is under Phase 3 evaluation with an SPA agreement from the FDA for treating acute ST-segment elevation myocardial infarction (STEMI).
• Novel approaches such as stem cell therapies and anti-inflammatory agents like Dapansutrile are being explored to improve outcomes and reduce cardiac injury post-myocardial infarction.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath